Wellcome U3B en es it fr

Wellcome U3B Brand names, Wellcome U3B Analogs

Wellcome U3B Brand Names Mixture

  • No information avaliable

Wellcome U3B Chemical_Formula


Wellcome U3B RX_link


Wellcome U3B fda sheet

Wellcome_U3B FDA

Wellcome U3B msds (material safety sheet)

Wellcome_U3B MSDS

Wellcome U3B Synthesis Reference

Elion et al.; J.Amer.Chem.Soc.; 81;1898,1901 (1959)

Wellcome U3B Molecular Weight

167.193 g/mol

Wellcome U3B Melting Point

>360 oC

Wellcome U3B H2O Solubility

36.3 mg/mL

Wellcome U3B State


Wellcome U3B LogP


Wellcome U3B Dosage Forms

Oral tablets

Wellcome U3B Indication

For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.

Wellcome U3B Pharmacology

Thioguanine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Thioguanine was first synthesized and entered into clinical trial more than 30 years ago. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Thioguanine is cross-resistant with mercaptopurine. Cytotoxicity is cell cycle phase-specific (S-phase).

Wellcome U3B Absorption

Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)

Wellcome U3B side effects and Toxicity

Oral, mouse: LD50 = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.

Wellcome U3B Patient Information


Patients should be informed that the major toxicities of thioguanine are related to
myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Patients should never
be allowed to take the drug without medical supervision and should be advised to consult
their physician if they experience fever, sore throat, jaundice, nausea, vomiting, signs
of local infection, bleeding from any site, or symptoms suggestive of anemia. Women of
childbearing potential should be advised to avoid becoming pregnant.

Wellcome U3B Organisms Affected

Humans and other mammals